Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Rating of “Buy” by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average recommendation of “Buy” by the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $12.6250.

A number of research analysts have issued reports on CATX shares. UBS Group lifted their price objective on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. B. Riley Financial lifted their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. HC Wainwright lifted their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, Truist Financial set a $12.00 price objective on Perspective Therapeutics in a report on Tuesday, March 17th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CATX. Commodore Capital LP acquired a new position in Perspective Therapeutics during the 1st quarter worth about $26,424,000. Avidity Partners Management LP grew its holdings in Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares during the last quarter. Vanguard Group Inc. grew its holdings in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after acquiring an additional 163,532 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after acquiring an additional 2,864,582 shares during the last quarter. Finally, Spruce Street Capital LP bought a new stake in Perspective Therapeutics during the 1st quarter worth about $10,955,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Trading Down 3.3%

CATX opened at $2.93 on Thursday. The firm’s fifty day moving average price is $4.02 and its two-hundred day moving average price is $3.76. Perspective Therapeutics has a fifty-two week low of $1.96 and a fifty-two week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. On average, sell-side analysts anticipate that Perspective Therapeutics will post -1.13 EPS for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.